You are here: Industry Insights > china

News List

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China PharmaSources
May 16, 2025
InnoCare Pharma announced today that the first patient has been dosed in the Phase II/III clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment patients with non-segmental vitiligo in China.
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China ACN Newswire
May 07, 2025
Everest Medicines announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA).
InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA PharmaSources
May 06, 2025
InnoCare Pharma announced today that its new generation pan-TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the CDE of China NMPA.
Comparison of Improved New Drugs Paths between China and the United States and Analysis of R&D Status in China Kevin
April 28, 2025
This article describes successful practices from the United States 505(b)(2) pathway and analyzes R&D status of China's modified new drugs.
InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China PharmaSources
April 27, 2025
InnoCare Pharma announced that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) for the first-line treatment of patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for CLL/SLL Patients in China PharmaSources
March 28, 2025
InnoCare announced the first patient dosed in the Phase III trial of ICP-248 combined with orelabrutinib for CLL/SLL. It's a potential treatment, with other trials advancing.
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China PharmaSources
March 20, 2025
InnoCare announced the first patient dosing in the Phase III trial of ICP - 488 for psoriasis. It showed good results in Phase II, aiming to meet unmet needs.
A Decade of Transformation in China's Innovative Drug Industry: The Journey from Follower to Leader Kevin
March 14, 2025
Over the past decade, China's innovative drug market has experienced remarkable transformation and growth. With the combined drive of policies, technology, and capital, China's innovative drug industry has entered a golden period of growth. This paper pro
InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China PharmaSources
February 18, 2025
InnoCare Pharma announced on Feb. 17, 2025 that CDE approved the Phase III trial of ICP - 248 combined with orelabrutinib for first - line CLL/SLL treatment in China.
A Record High! A Review of Blockbuster New Drugs in China in 2024, with the Number of Innovative Drugs Reaching New Heights! Sophia
January 23, 2025
In 2024, China's pharmaceutical field thrived. NMPA approved 220 new drugs, including 46 Class 1 innovative ones with anti-tumor drugs being the most. New anti-tumor drugs offered hope, and the R&D environment will keep improving.